Harvard Catalyst Profiles

Contact, publication, and social network information about Harvard faculty and fellows.

Aarti Asnani, M.D.

Title
Institution
Department
Address
Phone
Fax

Research
The research activities and funding listed below are automatically derived from NIH ExPORTER and other sources, which might result in incorrect or missing items. Faculty can login to make corrections and additions.
  1. K08HL145019 (ASNANI, AARTI) Jan 15, 2019 - Dec 31, 2023
    NIH
    CYP1 Inhibition as a New Therapeutic Strategy for Doxorubicin Cardiomyopathy
    Role: Principal Investigator

Bibliographic
Publications listed below are automatically derived from MEDLINE/PubMed and other sources, which might result in incorrect or missing publications. Faculty can login to make corrections and additions.
Newest   |   Oldest   |   Most Cited   |   Most Discussed   |   Timeline   |   Field Summary   |   Plain Text
PMC Citations indicate the number of times the publication was cited by articles in PubMed Central, and the Altmetric score represents citations in news articles and social media. (Note that publications are often cited in additional ways that are not shown here.) Fields are based on how the National Library of Medicine (NLM) classifies the publication's journal and might not represent the specific topic of the publication. Translation tags are based on the publication type and the MeSH terms NLM assigns to the publication. Some publications (especially newer ones and publications not in PubMed) might not yet be assigned Field or Translation tags.) Click a Field or Translation tag to filter the publications.
  1. Raber I, Asnani A. Cardioprotection in cancer therapy: novel insights with anthracyclines. Cardiovasc Res. 2019 Apr 15; 115(5):915-921. PMID: 30726931.
    Citations:    
  2. Baumgartner C, Spath-Blass V, Niederkofler V, Bergmoser K, Langthaler S, Lassnig A, Rienmüller T, Baumgartner D, Asnani A, Gerszten RE. A novel network-based approach for discovering dynamic metabolic biomarkers in cardiovascular disease. PLoS One. 2018; 13(12):e0208953. PMID: 30533038.
    Citations:    Fields:    
  3. Yang S, Asnani A. Cardiotoxicities associated with immune checkpoint inhibitors. Curr Probl Cancer. 2018 07; 42(4):422-432. PMID: 30173878.
    Citations:    Fields:    
  4. Mukhopadhyay A, Faridi KF, Asnani A, Osborn EA, Yang JX, Phillips CT, York M. Chest Pain During Chemotherapy: A Case of Severe Myocardial Bridging. J Invasive Cardiol. 2018 Jul; 30(7):E61. PMID: 29958181.
    Citations:    Fields:    Translation:Humans
  5. Vohra A, Asnani A. Biomarker Discovery in Cardio-Oncology. Curr Cardiol Rep. 2018 05 25; 20(7):52. PMID: 29802472.
    Citations:    Fields:    
  6. Asnani A. Beta-Blockers for Primary Prevention of Anthracycline Cardiotoxicity: Not Quite Ready for Prime Time. J Am Coll Cardiol. 2018 May 22; 71(20):2291-2292. PMID: 29773156.
    Citations:    Fields:    
  7. Godishala A, Yang S, Asnani A. Cardioprotection in the Modern Era of Cancer Chemotherapy. Cardiol Rev. 2018 May/Jun; 26(3):113-121. PMID: 29608498.
    Citations:    Fields:    Translation:Humans
  8. Asnani A. Cardiotoxicity of Immunotherapy: Incidence, Diagnosis, and Management. Curr Oncol Rep. 2018 04 11; 20(6):44. PMID: 29644505.
    Citations:    Fields:    
  9. Asnani A, Zheng B, Liu Y, Wang Y, Chen HH, Vohra A, Chi A, Cornella-Taracido I, Wang H, Johns DG, Sosnovik DE, Peterson RT. Highly potent visnagin derivatives inhibit Cyp1 and prevent doxorubicin cardiotoxicity. JCI Insight. 2018 Jan 11; 3(1). PMID: 29321375.
    Citations:    Fields:    
  10. Francis SA, Asnani A, Neilan T, Scherrer-Crosbie M. Optimizing cardio-oncology programs for cancer patients. Future Oncol. 2015; 11(14):2011-5. PMID: 26198828.
    Citations:    Fields:    Translation:Humans
  11. Liu Y, Asnani A, Zou L, Bentley VL, Yu M, Wang Y, Dellaire G, Sarkar KS, Dai M, Chen HH, Sosnovik DE, Shin JT, Haber DA, Berman JN, Chao W, Peterson RT. Visnagin protects against doxorubicin-induced cardiomyopathy through modulation of mitochondrial malate dehydrogenase. Sci Transl Med. 2014 Dec 10; 6(266):266ra170. PMID: 25504881.
    Citations: 20     Fields:    Translation:HumansAnimalsCells
  12. Asnani A, Peterson RT. The zebrafish as a tool to identify novel therapies for human cardiovascular disease. Dis Model Mech. 2014 Jul; 7(7):763-7. PMID: 24973746.
    Citations: 26     Fields:    Translation:HumansAnimals
  13. Gerszten RE, Asnani A, Carr SA. Status and prospects for discovery and verification of new biomarkers of cardiovascular disease by proteomics. Circ Res. 2011 Aug 05; 109(4):463-74. PMID: 21817166.
    Citations: 21     Fields:    Translation:HumansAnimals
  14. Lewis GD, Farrell L, Wood MJ, Martinovic M, Arany Z, Rowe GC, Souza A, Cheng S, McCabe EL, Yang E, Shi X, Deo R, Roth FP, Asnani A, Rhee EP, Systrom DM, Semigran MJ, Vasan RS, Carr SA, Wang TJ, Sabatine MS, Clish CB, Gerszten RE. Metabolic signatures of exercise in human plasma. Sci Transl Med. 2010 May 26; 2(33):33ra37. PMID: 20505214.
    Citations: 76     Fields:    Translation:HumansAnimalsCells
  15. Lewis GD, Wei R, Liu E, Yang E, Shi X, Martinovic M, Farrell L, Asnani A, Cyrille M, Ramanathan A, Shaham O, Berriz G, Lowry PA, Palacios IF, Tasan M, Roth FP, Min J, Baumgartner C, Keshishian H, Addona T, Mootha VK, Rosenzweig A, Carr SA, Fifer MA, Sabatine MS, Gerszten RE. Metabolite profiling of blood from individuals undergoing planned myocardial infarction reveals early markers of myocardial injury. J Clin Invest. 2008 Oct; 118(10):3503-12. PMID: 18769631.
    Citations: 77     Fields:    Translation:HumansAnimalsCellsCTClinical Trials
  16. Lewis GD, Asnani A, Gerszten RE. Application of metabolomics to cardiovascular biomarker and pathway discovery. J Am Coll Cardiol. 2008 Jul 08; 52(2):117-23. PMID: 18598890.
    Citations: 52     Fields:    Translation:Humans
Local representatives can answer questions about the Profiles website or help with editing a profile or issues with profile data. For assistance with this profile: HMS/HSDM faculty should contact feedbackcatalyst.harvard.edu. For faculty or fellow appointment updates and changes, please ask your appointing department to contact HMS. For fellow personal and demographic information, contact HMS Human Resources at human_resourceshms.harvard.edu. For faculty personal and demographic information, contact HMS Office for Faculty Affairs at facappthms.harvard.edu.
Asnani's Networks
Click the
Explore
buttons for more information and interactive visualizations!
Concepts (76)
Explore
_
Co-Authors (22)
Explore
_
Similar People (60)
Explore
_
Same Department 
Explore
_
Physical Neighbors
_
Funded by the NIH/NCATS Clinical and Translational Science Award (CTSA) program, grant number UL1TR001102, and through institutional support from Harvard University, Harvard Medical School, Harvard T.H. Chan School of Public Health, Beth Israel Deaconess Medical Center, Boston Children's Hospital, Brigham and Women's Hospital, Massachusetts General Hospital and the Dana Farber Cancer Institute.